<DOC>
	<DOCNO>NCT00462787</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine , topotecan , vinorelbine , thiotepa , dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase I trial study side effect best dose clofarabine give together topotecan , vinorelbine , thiotepa , dexamethasone treat young patient relapse refractory acute leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Relapsed Refractory Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose clofarabine administer combination topotecan hydrochloride , vinorelbine ditartrate , thiotepa , dexamethasone young patient relapse refractory acute leukemia . - Evaluate antileukemic potential regimen patient . - Evaluate incidence severity treatment-related morbidity mortality patient treat regimen . - Develop new reinduction treatment regimen result patient clinical response little residual disease possible permit bone marrow transplantation subsequent remission ; maintain response long enough identify appropriate stem cell donor ; permit patient undergo stem cell transplantation free infection without vital organ dysfunction . OUTLINE : This nonrandomized , prospective , dose-escalation study clofarabine . Patients receive topotecan hydrochloride IV continuously 120 hour day 0-4 ; vinorelbine ditartrate 6-10 minute day 0 , 7 , 14 ; thiotepa IV 4 hour day 2 ; clofarabine IV 2 hour day 3-7 ; oral IV dexamethasone 3 time daily day 3 7-13 day 3 thereafter . Patients also receive filgrastim ( G-CSF ) subcutaneously daily begin day 8 continue blood count recover . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos clofarabine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity OR dose precede 2 3 patient experience dose-limiting toxicity . At least 6 patient treated MTD . After completion study treatment , patient follow week 4 week , twice month 6 month , month 2 year . PROJECTED ACCRUAL : A total 23 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must 1 follow diagnosis : Acute lymphoblastic leukemia ( ALL ) meet 1 follow criterion : Refractory initial induction two standard regimen Relapsed &lt; 24 month first complete response highrisk protocol OR refractory one standard reinduction regimen Second great relapse Acute myeloid leukemia , acute biphenotypic leukemia , acute undifferentiated leukemia meeting 1 follow criterion : Refractory initial induction First great relapse Must &gt; 20 % bone marrow blast , evidence recurrent disease extramedullary site No symptomatic CNS disease Patients asymptomatic CNS disease eligible approval principal investigator PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % OR Lansky PS 70100 % AST ALT &lt; 4 time upper limit normal Bilirubin &lt; 2.0 mg/dL ( unless liver involvement ) Creatinine within normal range age OR creatinine clearance &gt; 60 mL/min/1.73 m^2 Adequate cardiac function ( either asymptomatic prior risk factor , symptomatic , leave ventricular ejection fraction &gt; 50 % rest ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled viral , bacterial , fungal infection PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior clofarabine More 2 week since prior systemic chemotherapy At least 7 day since prior chemotherapy patient rapidly progressive disease recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>